Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

Published:2018-06-22 Issue:8 Volume:7 Page:3571-3581
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Mikkelsen Stine Ulrik¹^ORCID,Kjaer Lasse¹,Bjørn Mads Emil¹,Knudsen Trine Alma¹,Sørensen Anders Lindholm¹,Andersen Christen Bertel Lykkegaard¹,Bjerrum Ole Weis²,Brochmann Nana¹,Fassi Daniel El³⁴,Kruse Torben A.⁵,Larsen Thomas Stauffer⁶,Mourits-Andersen Hans Torben⁷,Nielsen Claus Henrik⁴,Pallisgaard Niels⁸,Thomassen Mads⁵,Skov Vibe¹^ORCID,Hasselbalch Hans Carl¹^ORCID

Affiliation:

1. Department of Hematology; Zealand University Hospital; Roskilde Denmark

2. Department of Hematology; Rigshospitalet; Copenhagen Denmark

3. Department of Hematology; Herlev University Hospital; Copenhagen Denmark

4. Institute for Inflammation Research; Rigshospitalet; Copenhagen Denmark

5. Department of Clinical Genetics; Odense University Hospital; Odense Denmark

6. Department of Hematology; Odense University Hospital; Odense Denmark

7. Department of Hematology; South-West Jutlandic Hospital; Esbjerg Denmark

8. Department of Pathology; Zealand University Hospital; Roskilde Denmark

Funder

Ruxolitinib (Jakavi®)

Novartis A/S

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1619/fullpdf

Reference39 articles.

1. New mutations and pathogenesis of myeloproliferative neoplasms;Vainchenker;Blood,2011

2. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?;Hasselbalch;Blood,2012

3. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I;Verstovsek;Haematologica,2015

4. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

5. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis;Cervantes;Blood,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

2. Mitochondrial RelA empowers mtDNA G-quadruplex formation for hypoxia adaptation in cancer cells;Cell Chemical Biology;2024-05

3. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia;British Journal of Haematology;2023-09-19

4. Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms;Cancers;2023-08-29

5. Mutations, inflammation and phenotype of myeloproliferative neoplasms;Frontiers in Oncology;2023-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3